Miguel Brito: Newborn Screening and Challenges in Follow-Up Care for Sickle Cell Disease in Angola
Miguel Brito, Research Coordinator at H&TRC – Health and Technology Research center, shared post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Highlights
Newborn screening of 13,000+ infants in Luanda, Angola, identified a sickle cell disease prevalence of 1.38%.
Sickle cell trait was common, affecting 20.31% of screened newborns.
Follow-up of diagnosed patients is challenging due to low disease literacy and socioeconomic barriers.
With: Catarina Ginete , Baba Inusa, Jocelyne Neto de Vasconcelos NBS and paper with the support of Arise Initiative.
And the support of Revvity for Diagnostics and H&TRC – Health and Technology Research Center”
Title: Newborn screening for sickle cell disease in Angola: Implementation challenges and emerging data on hemoglobinopathy prevalence
Authors: Miguel Brito, Catarina Ginete, Mariana Jacinto, Manuela Mendes, Hailton Soares, Roberto Afonso, Adriano Siatembo, Jocelyne Vasconcelos, Baba Inusa
Read the Full Article on Blood Cells, Molecules and Diseases
Stay updated with Hemostasis Today.
-
Apr 10, 2026, 16:36José Luis Ferreiro: After Stent Treatment in Heart Attack Patients How to Balance Bleeding and Clotting Risk
-
Apr 10, 2026, 15:54Niccolò Bitto: Answers to Some of the Most Frequently Asked Questions on Gene Therapy for Hemophilia
-
Apr 10, 2026, 15:52Tareq Abadl: Coombs Test Explained in a Simple and Clear Way
-
Apr 10, 2026, 15:10Jecko Thachil: Should We Consider Air Pollution as a Thrombophilic Marker?
-
Apr 10, 2026, 14:02Pablo Corral: Are Cholesterol and Inflammation Really Equal in Atherosclerosis?
-
Apr 10, 2026, 13:43Mohammed Alo։ How Low Should LDL Go in Secondary Prevention of Cardiovascular Disease
-
Apr 10, 2026, 13:21John Abraham: Telomere Biology Disorders – From Bench to Bedside
-
Apr 10, 2026, 01:19Heghine Khachatryan: When Vascular Fragility Defines Risk – Rethinking Hemostasis in LDS
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH